title: Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis.
abstract: OBJECTIVE
  The aim of this study was to evaluate the clinical efficacy and safety of high-dose imatinib (IM) for chronic myeloid leukemia (CML) patients by pooled published studies.
  
  
  METHODS
  Through searching the databases of PubMed, EMBASE, ASCO, ESMO, CNKI, and Wanfang, we collected open published clinical controlled trials-related high-dose IM treatment of CML. The pooled complete cytogenetic response (CCyR) and hematologic toxicities were calculated by the statistical software.
  
  
  RESULTS
  Seven studies were included in this study with 1137 cases received high-dose IM treatment and 958 cases received regular-dose IM treatment. The pooled results showed that patients received high-dose IM had higher CCyR compared with regular-dose with the odds ratio (OR) of 1.75 (95% confidence interval [95% CI]: 1.44-2.1, P < 0.05) and 1.58 (95% CI: 1.38-1.81, P < 0.05) in 6 and 12 months. However, the hematologic toxicities risk of neutropenia (OR = 1.76, 95% CI: 1.22-2.54) and thrombopenia (OR = 1.88, 95% CI: 1.42-2.50) were much higher in the high-dose group.
  
  
  CONCLUSIONS
  High-dose IM for CML treatment was superior to standard-dose IM in the aspects of CCyR, but the risk of developing neutropenia and thrombopenia was much higher.
authors.affiliation: Department of Hematology, The 6th Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, P.R. China.
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Hematology, The 6th Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, P.R. China.
authors.forename: Bingmu
authors.initials: B
authors.lastname: Fang
authors.affiliation: Department of Hematology, The 6th Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, P.R. China.
authors.forename: Jinhong
authors.initials: J
authors.lastname: Jiang
authors.affiliation: Department of Clinical Laboratory, The 6th Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, P.R. China.
authors.forename: Peng
authors.initials: P
authors.lastname: Wang
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D020732:Cytogenetic Analysis; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage* / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D016017:Odds Ratio; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D017594:Publication Bias; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate